Scienta Lab SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Scienta Lab SAS - overview
Established
2021
Location
Gif-sur-Yvette, -, France
Primary Industry
Biotechnology
About
Founded in 2021 by its CEO, Camille Bouget, CSO, Vincent Bouget, and CTO, Julien Duquesne, and based in Gif-sur-Yvette, France, Scienta Lab SAS operates as a biotechnology company that develops precision drugs for immunology and inflammation and provides time-to-drop analysis in clinical trials solutions. In December 2023, Scienta Lab SAS raised EUR 4 million in seed funding from unspecified investors. Scienta Lab offers a machine learning platform that integrates multimodal immunology datasets used for drug development and clinical strategies for immune-mediated inflammatory diseases. The company also supports patient diagnosis by ensuring the presence of diseases and providing personalization of treatment plans for individual patients by predicting the course of diseases and treatment outcomes.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.scientalab.com/
Verticals
Artificial Intelligence, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Scienta Lab SAS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.